In the last trading session, 6.7 million shares of the Iovance Biotherapeutics Inc (NASDAQ:IOVA) were traded, and its beta was 1.05. Most recently the company’s share price was $3.23, and it changed around -$0.18 or -5.28% from the last close, which brings the market valuation of the company to $1.06B. IOVA currently trades at a discount to its 52-week high of $14.23, offering almost -340.56% off that amount. The share price’s 52-week low was $2.70, which indicates that the current value has risen by an impressive 16.41% since then. We note from Iovance Biotherapeutics Inc’s average daily trading volume that its 10-day average is 11.13 million shares, with the 3-month average coming to 9.73 million.
Iovance Biotherapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.31. If we narrow it down even further, the data shows that 0 out of 13 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 1 recommended IOVA as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight.
Iovance Biotherapeutics Inc (NASDAQ:IOVA) trade information
Instantly IOVA has showed a red trend with a performance of -5.28% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 3.47 on recent trading dayincreased the stock’s daily price by 6.92%. The company’s shares are currently down -56.35% year-to-date, but still up 13.33% over the last five days. On the other hand, Iovance Biotherapeutics Inc (NASDAQ:IOVA) is -13.64% down in the 30-day period. We can see from the shorts that 75.19 million shares have been sold at a short interest cover period of 6.61 day(s).
The consensus price target as assigned by Wall Street analysts is $11.5, which translates to bulls needing to increase their stock price by 71.91% from its current value. Analyst projections state that IOVA is forecast to be at a low of $6 and a high of $17.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 4.17%.
IOVA Dividends
Iovance Biotherapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Feb-26.
Iovance Biotherapeutics Inc (NASDAQ:IOVA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.63% of Iovance Biotherapeutics Inc shares, and 84.01% of them are in the hands of institutional investors. The stock currently has a share float of 84.54%. Iovance Biotherapeutics Inc stock is held by 402.0 institutions, with VANGUARD GROUP INC being the largest institutional investor. By 2024-06-30, it held 9.7478% of the shares, which is about 25.95 million shares worth $208.12 million.
PERCEPTIVE ADVISORS LLC, with 9.1052% or 25.93 million shares worth $207.98 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 8.61 shares worth $27.81 million, making up 2.63% of all outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held roughly 7.06 shares worth around $22.8 million, which represents about 2.15% of the total shares outstanding.
